• 9 Posts
  • 2.4K Comments
Joined 2 years ago
cake
Cake day: August 13th, 2024

help-circle



  • What are you suggesting? do you see this “99%” as ruling out things that would not be useful in human medicine? To be frank it appears from my perspective that you are saying things about the murine model in comparison with humans, without any actual evidence to back up your assertions. Opinions offered without evidence may be dismissed without evidence, or so the saying goes. Do you want to elaborate? I’m pretty sure everyone would agree that mice and humans are not the same species.

    In support of the Murine Model, I will offer this: The Mighty Mouse: The Impact of Rodents on Advances in Biomedical Research https://pmc.ncbi.nlm.nih.gov/articles/PMC3987984/

    "Based on a report from the Tufts Center in 2001, it is estimated that of 5,000–10,000 compounds that enter the development pipeline, 250 will make it to preclinical trials and of those, only five will move into human clinical trials. Of those five, on average, only one will actually make it to market. "

    Your numbers are off, according to this, it’s more like 1/5,000-10,000 or 0.0002 to 0.0001. Regardless I’m curious what you are suggesting? Organoids? Yep, they are being used and it’s likely they will continue to improve.

    If you don’t wish to elaborate, that’s ok with me. I’ll just assume your assertions are baseless, and move on. Have a great day!









  • Link above is only to the abstract, with an additional link to figures and tables:

    Abstract Traditional vaccines target specific pathogens, limiting their scope against diverse respiratory threats. We describe an intranasal liposomal formulation combining toll-like receptor (TLR) 4 and 7/8 ligands with a model antigen, ovalbumin, that provided broad, durable protection in mice for at least 3 months against infection with SARS-CoV-2 and Staphylococcus aureus. In addition, the vaccine protected mice from other viruses (SARS-CoV-2, SARS, SCH014 coronavirus), bacteria (Acinetobacter baumannii), and allergens. Protection was mediated by persistent ovalbumin-specific CD4+ and CD8+ memory T cells that imprinted alveolar macrophages (AMs), enhancing antigen presentation and antiviral immunity. Following infection, vaccinated mice mounted rapid pathogen-specific T cell and antibody responses and formed ectopic lymphoid structures in the lung. These results reveal a class of “universal vaccines” against diverse respiratory 🩹

    The cool thing about this is the stimulation of CD4 & CD8+ memory cells imprinting alveolar (the alveoli of the lungs) macrophages, a type of Tissue Resident Macrophage (TRMs) that will then hang out in that location, where the invaders first appeared, waiting for them to return. Whereupon they will alert the immune system that “those guys” are back, you know what to do. I heard the process explained this way:

    TRMs are like that cowboy seemingly snoozing away, at the Old Saloon. Then when “those infectious guys” that had infected one before, and markers for them are imprinted on the TRMs show up, suddenly the guy snoozing away ‘wakes up’, saying “I remember YOU!” and alerts The Posse (Immune System) that it’s time to take action. The version I heard on TWIV was a bit cuter, but I edited this for clarity.